Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,897 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
Kaieda A, Takahashi M, Fukuda H, Okamoto R, Morimoto S, Gotoh M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Sugimoto H, Okada K, Snell G, Bertsch R, Nguyen J, Sang BC, Miwatashi S. Kaieda A, et al. Among authors: okada k. ChemMedChem. 2019 May 17;14(10):1022-1030. doi: 10.1002/cmdc.201900129. Epub 2019 Apr 18. ChemMedChem. 2019. PMID: 30945818
Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
Kaieda A, Takahashi M, Takai T, Goto M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Hamada T, Shirasaki M, Okada K, Snell G, Bragstad K, Sang BC, Uchikawa O, Miwatashi S. Kaieda A, et al. Among authors: okada k. Bioorg Med Chem. 2018 Feb 1;26(3):647-660. doi: 10.1016/j.bmc.2017.12.031. Epub 2017 Dec 24. Bioorg Med Chem. 2018. PMID: 29291937
Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2.
Kaieda A, Takahashi M, Fukuda H, Okamoto R, Morimoto S, Gotoh M, Miyazaki T, Hori Y, Unno S, Kawamoto T, Tanaka T, Itono S, Takagi T, Sugimoto H, Okada K, Lane W, Sang BC, Saikatendu K, Matsunaga S, Miwatashi S. Kaieda A, et al. Among authors: okada k. ChemMedChem. 2019 Dec 17;14(24):2093-2101. doi: 10.1002/cmdc.201900373. Epub 2019 Nov 7. ChemMedChem. 2019. PMID: 31697454
Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor.
Miyamoto N, Sakai N, Hirayama T, Miwa K, Oguro Y, Oki H, Okada K, Takagi T, Iwata H, Awazu Y, Yamasaki S, Takeuchi T, Miki H, Hori A, Imamura S. Miyamoto N, et al. Among authors: okada k. Bioorg Med Chem. 2013 Apr 15;21(8):2333-2345. doi: 10.1016/j.bmc.2013.01.074. Epub 2013 Feb 13. Bioorg Med Chem. 2013. PMID: 23498918
Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, Hori A, Imamura S. Matsumoto S, et al. Among authors: okada k. Bioorg Med Chem. 2013 Dec 15;21(24):7686-98. doi: 10.1016/j.bmc.2013.10.028. Epub 2013 Oct 30. Bioorg Med Chem. 2013. PMID: 24216091
5,897 results